Holen Sie sich die Stockscreener-App
13.26
14.71%
1.70
Handel nachbörslich:
13.25
-0.010
-0.08%
Schlusskurs vom Vortag:
$11.56
Offen:
$11.64
24-Stunden-Volumen:
2.43M
Relative Volume:
1.71
Marktkapitalisierung:
$624.41M
Einnahmen:
$217.11M
Nettoeinkommen (Verlust:
$-651.19M
KGV:
-1.0208
EPS:
-12.99
Netto-Cashflow:
$-387.26M
1W Leistung:
-5.01%
1M Leistung:
+32.87%
6M Leistung:
-2.14%
1J Leistung:
+18.01%
1-Tages-Spanne:
$11.45
$13.44
1-Wochen-Bereich:
$11.41
$14.28
52-Wochen-Spanne:
$5.00
$16.85
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Vergleichen Sie DNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
13.26 | 684.35M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
Ginkgo Bioworks Holdings, Inc. (DNA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Ginkgo Bioworks Holdings: Mixed Earnings Call with Strategic Growth Potential - AInvest
Ginkgo Bioworks Earnings Call: Mixed Sentiment and Strategic Growth - TipRanks
Ginkgo Bioworks Holdings Reports Q2 2025 Earnings: Revenue Down 12%, Net Loss Narrows by 72% - AInvest
Ginkgo Bioworks Holdings Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ginkgo Bioworks appoints Brian O’Sullivan as head of commercial By Investing.com - Investing.com Canada
Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth - MarketScreener
TR | OpenAI4o Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Raises Target Price to $12 - 富途牛牛
Ginkgo Bioworks: Assessing the Recent Rally for Potential Value - AInvest
Ginkgo Bioworks: Sell The Recent Rally (NYSE:DNA) - Seeking Alpha
Comparing Ginkgo Bioworks Holdings Inc. in custom built stock radarsFree Swing Trade Entry With Volume Triggers - Newser
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.33 - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2025 Earnings Call Transcript - Insider Monkey
Ginkgo achieves $250M cost-reduction goal early, bolsters financial position - The Business Journals
Ginkgo Bioworks stock price target raised to $16 from $12 at TD Cowen - Investing.com Australia
Ginkgo Bioworks shares rise 3.01% premarket after achieving $250 million cost reduction goal. - AInvest
Ginkgo Bioworks Holdings Inc (DNA) PT Raised to $16 at TD Cowen - StreetInsider
Ginkgo Bioworks Holdings Inc (DNA) Q2 2025 Earnings Call Highlights: Strategic Cost Management ... By GuruFocus - Investing.com Canada
Ginkgo Bioworks Q2 2025 Earnings Call Transcript: Progress Towards Adjusted EBITDA Breakeven and Life Science Tools Expansion - AInvest
Ginkgo Bioworks Holdings, Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Reports Q2 2025 Financial Results - TipRanks
Ginkgo Bioworks Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ginkgo Bioworks Q2 2025 Earnings Call Transcript - MarketBeat
Ginkgo Bioworks Holdings: Strong Growth Potential Amidst Biosecurity Revenue Challenges - TipRanks
Ginkgo Bioworks Reports Second Quarter 2025 Financial Results - The Malaysian Reserve
Ginkgo Bioworks Struggles As Biosecurity Revenue Slips - Finimize
Ginkgo Bioworks Holdings, Inc. SEC 10-Q Report - TradingView
Ginkgo Bioworks Q2 EPS -$1.10, Revenue $50M, FY25 Outlook Reaffirmed - AInvest
Ginkgo Bioworks Announces Q2 Earnings Presentation on Aug. 7, 2025 - AInvest
Ginkgo Bioworks Q2 Earnings Preview: Key Figures and Estimates - AInvest
Bank of New York Mellon Corp Raises Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
What makes Ginkgo Bioworks Holdings Inc. stock price move sharplyTechnical Reversal Setup with Risk Limits - Newser
Ginkgo Bioworks Holdings Inc expected to post a loss of $1.57 a shareEarnings Preview - TradingView
Ginkgo Bioworks Holdings Inc (DNA) Stock: A Year of Decreases and Increases - investchronicle.com
Quant Strategy Flags Ginkgo Bioworks Holdings Inc. for EntryLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Traders Consider Averaging Down in Ginkgo Bioworks Holdings Inc.Secure Return Focused Investment Plan Released - beatles.ru
How does Ginkgo Bioworks Holdings Inc. generate profit in a changing economyFree Investment Risk Control - Jammu Links News
Ginkgo Bioworks Holdings Inc. Stock Analysis and ForecastAccelerated wealth expansion - Jammu Links News
What catalysts could drive Ginkgo Bioworks Holdings Inc. stock higher in 2025Master stock selection with insider knowledge - Jammu Links News
What is the dividend policy of Ginkgo Bioworks Holdings Inc. stockExceptional profit potential - Jammu Links News
When is Ginkgo Bioworks Holdings Inc. stock expected to show significant growthGet alerts on the hottest stocks daily - Jammu Links News
Is it the right time to buy Ginkgo Bioworks Holdings Inc. stockBreakneck growth rates - Jammu Links News
How does Ginkgo Bioworks Holdings Inc. compare to its industry peersAchieve impressive returns with smart timing - Jammu Links News
What is the risk reward ratio of investing in Ginkgo Bioworks Holdings Inc. stockReal Time Planner For Fast Growth - jammulinksnews.com
Is Ginkgo Bioworks Holdings Inc. stock overvalued or undervaluedBeginner Investor Watchlist For 2025 - Jammu Links News
Ginkgo Bioworks shares fall 6.39% premarket ahead of Q2 2025 earnings presentation. - AInvest
Does Ginkgo Bioworks Holdings Inc. stock perform well during market downturnsAdvanced Screener Alerts That Work - Jammu Links News
Ginkgo Bioworks awarded $4.66M contract by PNNL - Yahoo Finance
Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation - 富途牛牛
Ginkgo Bioworks stock rises after securing $4.66M automation contract By Investing.com - Investing.com Canada
Ginkgo Bioworks Secures $4.66M Federal Contract for Revolutionary Lab Automation System at PNNL - Stock Titan
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):